Clinical Trials Logo

T-cell Prolymphocytic Leukemia clinical trials

View clinical trials related to T-cell Prolymphocytic Leukemia.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05978141 Recruiting - Clinical trials for Angioimmunoblastic T-cell Lymphoma

A Registry for People With T-cell Lymphoma

Start date: July 27, 2023
Phase:
Study type: Observational [Patient Registry]

The purpose of this registry study is to create a database-a collection of information-for better understanding T-cell lymphoma. Researchers will use the information from this database to learn more about how to improve outcomes for people with T-cell lymphoma.

NCT ID: NCT05823571 Recruiting - Multiple Myeloma Clinical Trials

Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older Patients

Start date: July 6, 2023
Phase: Phase 1
Study type: Interventional

This research is being done to learn whether drug called itacitinib, which is a novel inflammation- and immune-lowering drug (immunosuppressant), can be given before and after non-myeloablative peripheral blood stem cell transplantation (PBSCT; also known as a 'mini' transplant) to help prevent certain complications such as cytokine release syndrome (CRS) for patients with blood cancers, using peripheral blood from a relative. The investigators will also examine if by using itacitinib the investigators can reduce the duration of MMF (other immune suppressive drug administration posttransplant).

NCT ID: NCT04771572 Recruiting - Multiple Myeloma Clinical Trials

Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.

Start date: August 23, 2021
Phase: Phase 1
Study type: Interventional

This is a Phase 1, multi-center, open-label study with a dose-escalation phase (Phase 1a) and a cohort expansion phase (Phase 1b), to evaluate the safety, tolerability, and PK profile of LP-118 under a once daily oral dosing schedule in up to 100 subjects.

NCT ID: NCT02742727 Recruiting - Clinical trials for Acute Myeloid Leukemia

CAR-pNK Cell Immunotherapy in CD7 Positive Leukemia and Lymphoma

Start date: March 2016
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and effectiveness of CAR-pNK cell immunotherapy in patients with CD7 positive relapsed or refractory Leukemia and Lymphoma.